Description
Carfilzomib-dexamethasone: a new ‘best in class’ in multiple myeloma
Article: Carfilzomib-dexamethasone: a new ‘best in class’ in multiple myeloma
€3.03
Related products
-
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart -
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart -
Article: Highlights in genitourinary cancers
€3.03 Add to cart -
1 year subscription print edition of the Belgian Journal of Hematology (BJH)
€209.83 Add to cart
Reviews
There are no reviews yet.